Oxford Biomedica plc (LON:OXB) announced an agreement to licence its LentiVector platform to NASDAQ-listed Beam Therapeutics.
Beam will use apply the suite of technologies to its CAR-T programmes in oncology, which engineer the patient’s cells to target tumours.
FTSE 250-listed Oxford Biomedica will receive an undisclosed upfront payment, payments related to lentiviral vectors for use in clinical trials, plus development and regulatory milestones alongside an undisclosed royalty on the net sales of the final products.
The pair are also working on a pre-clinical programme.
It is Oxford Biomedica’s announced partnership with developers in the CAR-T field, after Novartis and Bristol Myers Squibb.
“We see it as further confirmation after last week’s new three-year clinical supply agreement with Axovant that OXB’s underlying business continues to develop apace,” analysts at house broker Peel Hunt commented.
“The addition of a new partner, with potential to add multiple further projects in one of OXB’s core areas of expertise – CAR-T – is also a clear positive.”
Shares added 1% to 828.1p on Monday at the opening bell.
Published at Mon, 03 Aug 2020 07:24:00 +0000-Oxford Biomedica secures third partnership in CAR-T field